Person:

Tsherniak, Aviad

Loading...
Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Tsherniak

First Name

Aviad

Name

Tsherniak, Aviad

Search Results

Now showing 1 - 2 of 2
  • Publication

    The Landscape of Cancer Cell Line Metabolism

    (Springer Science and Business Media LLC, 2019-05) Li, Haoxin; Ning, Shaoyang; Gopal, Shuba; Deik, Amy; Souza, Amanda; Pierce, Kerry; Keskula, Paula; Hernandez, Desiree; Ann, Julie; Shkoza, Dojna; Apfel, Verena; Zou, Yilong; Vazquez, Francisca; Barretina, Jordi; Tsherniak, Aviad; Giannakis, Marios; Ghandi, Mahmoud; Kryukov, Gregory; Pagliarini, Raymond; Galli, Giorgio; Root, David; Hahn, William; Schreiber, Stuart; Clish, Clary; Garraway, Levi; Sellers, William

    Despite considerable efforts to identify cancer metabolic alterations that might unveil druggable vulnerabilities, systematic characterizations of metabolism as it relates to functional genomic features and associated dependencies remain uncommon. To further understand the metabolic diversity of cancer, we profiled 225 metabolites in 928 cell lines from more than 20 cancer types in the Cancer Cell Line Encyclopedia (CCLE) using liquid chromatography–mass spectrometry (LC-MS). This resource enables unbiased association analysis linking the cancer metabolome to genetic alterations, epigenetic features and gene dependencies. Additionally, by screening barcoded cell lines, we demonstrated that aberrant ASNS hypermethylation sensitizes subsets of gastric and hepatic cancers to asparaginase therapy. Finally, our analysis revealed distinct synthesis and secretion patterns of kynurenine, an immune-suppressive metabolite, in model cancer cell lines. Together, these findings and related methodology provide comprehensive resources that will help clarify the landscape of cancer metabolism.

  • Publication

    WRN Helicase is a Synthetic Lethal Target in Microsatellite Unstable Cancers

    (Cold Spring Harbor Laboratory, 2018-12-21) Bass, Adam; Chan, Edmond; Shibue, Tsukasa; McFarland, James; Gaeta, Benjamin; Ghandi, Mahmoud; Dumont, Nancy; Gonzalez, Alfredo; McPartlan, Justine; Li, Tianxia; Zhang, Yanxi; Liu, Jie Bin; Lazaro, Jean-Bernard; Gu, Peili; Piett, Cortt; Apffel, Annie; Ali, Syed Omar; Deasy, Rebecca; Keskula, Paula; Ng, Raymond; Roberts, Emma; Reznichenko, Elizaveta; Leung, Lisa; Alimova, Maria; Schenone, Monica; Islam, Manirul; Maruvka, Yosef; Liu, Yang; Roper, Jatin; Raghavan, Srivatsan; Giannakis, Marios; Tseng, Yuen-Yi; Nagel, Zachary; D’Andrea, Alan; Root, David; Boehm, Jesse; Getz, Gad; Chang, Sandy; Golub, Todd; Tsherniak, Aviad; Vazquez, Francisca

    Synthetic lethality, an interaction whereby the co-occurrence of two genetic events leads to cell death but one event alone does not, can be exploited for cancer therapeutics1. DNA repair processes represent attractive synthetic lethal targets since many cancers exhibit an impaired DNA repair pathway, which can lead to dependence on specific repair proteins2. The success of poly (ADP-ribose) polymerase 1 (PARP-1) inhibitors in homologous recombination-deficient cancers highlights the potential of this approach3. Hypothesizing that other DNA repair defects would give rise to synthetic lethal relationships, we queried dependencies in cancers with microsatellite instability (MSI), which results from deficient DNA mismatch repair (dMMR). Here we analyzed data from large-scale CRISPR/Cas9 knockout and RNA interference (RNAi) silencing screens and found that the RecQ DNA helicase WRN was selectively essential in MSI models in vitro and in vivo, yet dispensable in microsatellite stable (MSS) models. WRN depletion induced double-strand DNA breaks and promoted apoptosis and cell cycle arrest selectively in MSI models. MSI cancer models required the helicase activity, but not the exonuclease activity of WRN. These findings expose WRN as a synthetic lethal vulnerability and promising drug target for MSI cancers.